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Abstract
Purpose—Younger women (under age 45 years) diagnosed with breast cancer often face more 
aggressive tumors, higher treatment intensity, lower survival rates, and greater financial hardship. 
The purpose of this study was to estimate breast cancer costs by stage at diagnosis during the first 
18 months of treatment for privately insured younger women.
Methods—We analyzed North Carolina cancer registry data linked to claims data from private 
insurers from 2003 to 2010. Breast cancer patients were split into two cohorts: a younger and older 
group aged 21–44 and 45–64 years, respectively. We conducted a cohort study and matched 
women with and without breast cancer using age, ZIP, and Charlson Comorbidity Index. We 
calculated mean excess costs between breast cancer and non-breast cancer patients at 6, 12, and 18 
months.
Results—For younger women, AJCC 6th edition stage II cancer was the most common at 
diagnosis (40%), followed by stage I (34%). On the other hand, older women had more stage I 
(46%) cancer followed by stage II (34%). The excess costs for younger and older women at 12 
months were $97,486 (95% confidence interval [CI] $93,631–101,341) and $75,737 (95% CI 
$73,962–77,512), respectively. Younger breast cancer patients had both a higher prevalence of 
later-stage disease and higher within-stage costs.
Conclusions—The study reports high costs of treatment for both younger and older women than 
a non-cancer comparison group; however, the estimated excess cost was significantly higher for 
younger women. The financial implications of breast cancer treatment costs for younger women 
need to be explored in future studies.
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Introduction
Over 22,000 women younger than 45 years of age (henceforth ‘‘younger women’’) were 
diagnosed with breast cancer in 2013 [1]. Although less than 10% of all breast cancers are 
diagnosed among women younger than age 45, the types of breast cancer younger women 
face are typically more aggressive, are diagnosed at more advanced stages, and result in 
poorer survival compared to breast cancer in older women [2–4]. For these reasons, the 
Breast Cancer Education and Awareness Requires Learning Young (EARLY) act and prior 
research have identified woman under the age of 45 years to be particularly burdened by 
breast cancer [5, 6]. Younger women may also experience higher treatment intensity and 
have cancers that are less responsive to treatment, and have distinct and more prevalent side 
effects from treatment than older women [3, 7–9]. These side effects can include poorer 
quality of life, fertility problems, and depression [9, 10].
As a result, breast cancer treatment for younger women is expensive, making them 
vulnerable to financial hardship [11, 12]. Recent research has shown that 31.8% of cancer 
survivors are likely to have cancer treatment-induced financial troubles, with higher rates 
among younger cancer patients [13, 14]. These financial difficulties cause some survivors to 
forego or delay necessary medical treatments [12, 14]. Further, younger women also face 
substantial productivity losses as a result of breast cancer treatment [15].
Previous work has investigated the costs of breast cancer treatment among privately insured 
women by age group and stage at diagnosis [11, 16–19]. Among these studies, only one 
addressed the costs of breast cancer treatment in younger women [11]. Two studies 
addressed treatment costs for women with mean age between 52 and 55 years regardless of 
stage at diagnosis [16, 17]. However, two other studies estimated treatment costs by stage for 
women under the age of 65 [18, 19]. To our knowledge, no peer-reviewed study presents the 
economic costs of breast cancer treatment by stage at diagnosis in younger, privately insured 
women.
Another limitation of the current literature on breast cancer costs in younger women is that, 
with the exception of Blumen et al. [19], all of these studies present prevalent, not incident, 
costs. Prevalent or annual costs provide a view of costs for a cross section of women across 
the spectrum of the treatment continuum. Incident costs, in contrast, provide cost estimates 
from the onset of disease until the end of the disease or a specific period of time, typically a 
year [20, 21]. For chronic diseases, such as cancer, incident cost estimates provide more 
information that can be used when evaluating prevention strategies. In their estimates of 
prevalent costs, Allaire et al. [11] attempt to identify annual costs for women in the active 
treatment phase via procedure codes but do not identify a diagnosis date. Blumen et al. [19] 
rely on a claim-based algorithm to infer cancer stage at diagnosis. These solutions are 
imperfect at capturing incident costs as they lack the data to fully identify the date of 
diagnosis and then follow women over the course of treatment.
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The current study overcomes these limitations by estimating incident breast cancer treatment 
costs by stage at diagnosis for privately insured younger women. Specifically, we estimate 
the medical costs of treating privately insured younger women with breast cancer from the 
date of diagnosis. We also investigate whether treatment costs are a result of a later stage of 
diagnosis or higher treatment utilization within stage. Providing estimates by stage is critical 
because stage at diagnosis has been shown to substantially influence treatment costs [19]. 
The economic impact of stage at diagnosis is relevant to our understanding of how this 
disease affects younger women and their families during and after treatment.
Methods
Data
We analyzed 2003–2010 North Carolina Central Cancer Registry data linked to private 
insurers’ enrollment files for the same period as this was the most recent linked dataset 
available. The data were maintained by the Integrated Cancer Information and Surveillance 
System at the University of North Carolina and covered approximately 85% of the North 
Carolina population diagnosed with cancer and approximately 60% of the total North 
Carolina population [22]. The Institutional Review Board at RTI International and the 
University of North Carolina approved the research plan for this study.
The cancer registry file contains demographic characteristics including ZIP code, primary 
cancer site, cancer staging using the American Joint Committee on Cancer (AJCC) 6th 
edition definitions, date of diagnosis, and date of death. The private insurer data include the 
following data files: enrollment, inpatient hospital, outpatient hospital, physician office, and 
prescription drug. The enrollment data file contains effective date of enrollment, the 
enrollment termination date, demographics, and cancer registry link identifier.
Cost estimation
Our estimation proceeded in several steps. First, we set the inclusion/exclusion criteria for 
the breast cancer sample. Then, we set the enrollment criteria and set up the comparison 
population for matching. Next, we conducted an exact match to find women with the same 
covariates as our sample of women with breast cancer. Finally, we estimated mean excess 
costs for the breast cancer sample by subtracting off the mean medical costs of the 
comparison population.
The breast cancer sample included women who were diagnosed with invasive primary breast 
cancer between ages 18 and 64 years. We excluded those who died within 1 year of 
diagnosis so we could observe 6 months of cancer claims data while allowing for a 6-month 
buffer for end-of-life costs. We included cancer patients who were enrolled for at least 3 
months prior to their diagnosis so we could estimate a Charlson Comorbidity Index (CCI) 
using pre-cancer diagnosis data. Cancers were excluded from the CCI [23].
We included breast cancer patients and non-breast cancer comparison patients in our 
analysis only if the patients were continuously enrolled in each of the follow-up periods 
analyzed (6, 12, and 18 months), known as the initial phase of care [24]. We defined 
continuous enrollment as being enrolled for at least 1 day in consecutive months. In addition 
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to our younger cohort of women with breast cancer, we also estimated costs at 12 months for 
a cohort of women aged 45–64 years. We followed all the same sample restrictions and 
matching procedures as we did with the younger women with breast cancer. These were 
conducted as an additional comparison population to younger women with breast cancer.
We compared the costs between breast cancer patients and a comparison population of 
female, non-breast cancer patients who were enrolled in private insurance between 2003 and 
2010. We excluded all patients in the population without breast cancer who died and who 
had inconsistent birth date information across enrollment periods. The final sample of 
younger women with breast cancer included 1106 women enrolled at 6 months, 955 enrolled 
at 12 months, and 805 enrolled at 18 months.
We conducted an exact match between the breast cancer patients and patients without breast 
cancer using categorical 5-year birth year groups (1960–1964, 1965–1969, 1970–1974, 
1975–1979, 1980–1984, 1985–1989), ZIP code, and CCI (0, ≥1). The non-breast cancer 
sample was given a pseudo-diagnosis date, the same diagnosis date as its matched patient 
with breast cancer. This date was used as an index date for coverage and cost estimation. 
The exact match resulted in 167,681 younger women matched at 6 months, 134,427 at 12 
months, and 109,218. We retained all matches and used weights to control for the varying 
number of non-breast cancer patients per cancer case [25].
We estimated total private insurance medical payments for three follow-up periods (6, 12, 
and 18 months from diagnosis) for the younger breast and non-breast cancer cohorts and for 
one follow-up period (12 months from diagnosis) for the older breast and non-breast cancer 
cohorts. For the older breast and non-breast cancer cohorts, we summed monthly payments 
for 12 months from diagnosis. Payments were estimated separately for expenditures related 
to the following services for all cohorts: physician office visits, outpatient visits, inpatient 
hospital stays, and prescription drugs. We calculated excess costs as the difference in mean 
payments between the patients with and without breast cancer by (1) type of expenditure and 
(2) type of expenditure by stage. Additionally, payments were estimated by stage of cancer 
for the younger breast cancer patients [26]. All costs were inflated to 2014 dollars using a 
gross domestic product deflator [27]. All estimates were generated using Stata 13.1 (College 
Station, TX).
Results
Table 1 compares the age categories, CCI, and cancer stage of younger compared to older 
breast cancer patients. The average age at diagnosis was 39 years (range 21–44) for younger 
breast cancer patients and 55 years (range 45–64) for older patients. Overall, 96 and 89% of 
younger and older women, respectively, had a CCI of zero in the 3 months prior to their 
diagnosis. For younger women at 12 months, stage II was the most common stage at 
diagnosis (40%), followed by stage I cancer (34%). Older women had a significantly higher 
percentage of stage I cancer (46%) and lower percentage of stage II (34%). Enrollment for 
younger breast cancer patients was stable with 73% (805/1106) of those enrolled at 6 
months still enrolled at 18 months.
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Private insurance costs were significantly higher among younger women with breast cancer 
than those without breast cancer for all services at all points in time (Table 2). The excess 
costs at 12 months relative to no cancer were $97,486 (confidence interval [CI] $93,631–
101,341). Hospital outpatient and physician services costs were the largest drivers, with 
excess costs of $43,453 (CI $40,256–46,650) and $47,644 (CI $45,154–50,134) at 12 
months, respectively.
Table 3 presents the treatment cost of older women with and without breast cancer among 
those continuously enrolled for 12 months. In this older population, the estimated excess 
cost of $75,737 (CI $73,962–77,512) at 12 months was significantly higher among older 
women compared to those without breast cancer. Additionally, in the 12 months after 
diagnosis, the estimated excess cost among younger women with breast cancer was $97,486 
(Table 2), which was significantly higher than that of older women estimated to be $75,737 
(Table 3).
Figure 1 presents the average monthly medical costs for younger non-breast cancer controls 
and breast cancer patients by stage at diagnosis. The overall pattern in average monthly costs 
is similar among each cancer stage: highest costs during the first year and a downward trend 
that tapers off at about 1 year after diagnosis. Generally, costs that occur after the first 12 
months of care are known as ‘‘continuing’’ phase of care. [28] The comparison population 
experienced stable costs over the whole time period. Stage II patients and patients with an 
unknown stage converge closely toward the end of the 18 months, at around $2000 per 
month. Stage III/IV breast cancer patients maintained an average monthly cost of about 
$5000 1 year after diagnosis with a spike in costs at 15 months.
Figure 2 shows excess costs at 12 months by service type and stage of cancer across younger 
and older breast cancer patients. For younger women, the excess costs at 12 months after 
diagnosis ranged from $72,177 for stage I to $131,812 for stages III/IV, whereas for older 
women, the excess costs ranged from $53,288 for stage I to $124,237 for stages III/IV. 
Treatment costs increased with cancer stage within each service category, with physician and 
outpatient services having the highest excess costs for each stage.
Discussion
Younger breast cancer patients not only have a higher proportion of later-stage cancer than 
older women, but also have higher within-stage excess costs. Breast cancer treatment costs 
for younger women are substantial; estimated excess costs at 6, 12, and 18 months were 
$65,189, $97,486, and $108,857, respectively. Younger women with stage I cancer have the 
largest difference with an excess cost (relative to older women) of $18,889, whereas stages 
II and III/IV have smaller differences of $12,790 and $7575, respectively.
These differences in costs could reflect the more intensive treatment offered to younger 
patients diagnosed with breast cancer even at an early stage; 5 years of adjuvant tamoxifen is 
considered endocrine treatment for premenopausal women with estrogen [29, 30]. Higher 
excess costs may also be the result of younger breast cancer patients diagnosed with more 
aggressive forms of breast cancers that tend to progress faster [31]. Treating more aggressive 
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cancer requires more intensive combination chemotherapies, which may underlie the higher 
costs reported in this study and previous studies [18, 19]. This evidence dovetails with recent 
research indicating that tumor histology has shown to be more predictive of effective 
treatment than age [29, 32].
Breast cancer patients incurred markedly higher costs for the initial 12-month period after 
diagnosis after which the costs tend to stabilize, but remain higher compared to individuals 
without a breast cancer diagnosis regardless of age. The largest cost components by type of 
service are physician office and hospital outpatient costs, which accounted for almost 90% 
of the total cost difference between those with breast cancer and the comparison cohort, 
regardless of age. Costs also vary by stage at diagnosis for younger women, with treatment 
costs estimated to be much lower for stage I ($72,177) than for stage III/IV ($105,254) at 12 
months. The difference in breast cancer treatment costs by stage at diagnosis has been 
reported in prior studies, but these studies did not estimate costs for younger women [19, 33, 
34].
One of the key strengths of this study was the ability to report costs for younger women 
diagnosed with breast cancer based on linked administrative and cancer registry data. This 
allowed us to capture incident breast cancer costs occurring from the date of diagnosis, 
rather than rely on an algorithm to detect the stage at diagnosis [19] or prevalent-based costs 
reported in previous work [11]. Using cancer registry data by stage at diagnosis also enabled 
us to examine whether costs for younger women were higher because of a later stage at 
diagnosis or greater treatment utilization within stage. Finally, we leveraged the size of our 
claims data to construct two separate cost comparisons for younger women: a sample of 
women without breast cancer to properly capture the attributable costs, and a group of older 
women diagnosed with breast cancer.
This study has several limitations. First, we only analyzed data from private insurers in one 
state; therefore, the findings reported here may not be reflective of the treatments or 
resources used in other settings. Second, we did not have a large enough sample of patients 
to assess cost of stages III and IV separately; thus, we report pooled costs for stage III and 
IV breast cancer patients, and the cost of treatment may differ for these two stages [19]. 
Third, the encounter data may not have captured all diagnoses included in the CCI. The 
imprecision of the CCI measurement could bias the results either up or down. Fourth, the 
study population displayed a surprising amount of stability in maintaining insurance 
coverage over time, which may limit generalization of our findings to populations that 
remain in a similar occupation or geographic area over time. Fifth, owing to data limitations, 
we could not generate estimates by race/ethnicity or by hormone receptor status. Future 
research should seek to diversify these estimates at these levels.
This study offers an important contribution to the literature on the incidence-based cost of 
breast cancer treatment for privately insured younger women by stage at diagnosis. 
Incidence-based cost estimates are especially important for chronic diseases such as cancer, 
where prevalence-based costing provides a cross section of patients along the treatment 
spectrum. Incidence-based costs are also critical for future research as inputs into cost-
effectiveness analyses for decision making [20].
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The treatment costs of breast cancer in younger women are high and increase with the stage 
at diagnosis. Screening by mammography can help detect breast cancer at earlier stages and 
is recommended for women ages 50–74 [35]; however, screening has not been shown to be 
effective for younger women [29]. The EARLY Act authorized the Centers for Disease 
Control and Prevention (CDC) to conduct research and develop initiatives to advance 
understanding and awareness of breast cancer among young women [5]. CDC’s digital 
media campaign Bring Your Brave promotes awareness of breast health and breast cancer in 
young women [36]. Consideration also needs to be given to research leading to a better 
understanding of the influence primary preventive factors (e.g., environmental exposures, 
genetic predisposition, etc.) on early onset disease [37].
The high cost of treatment underscores the importance obtaining and retaining insurance 
coverage for younger women. Psychological financial hardship, the mental distress related to 
meeting financial obligations, occurs much more frequently among the uninsured [38]. In 
addition, insurance coverage may be associated with breast cancer diagnosed at an earlier 
stage, meaning that having insurance coverage could reduce the public health burden of 
treatment considerably [39]. Researchers have found that cancer survivors with insurance are 
much less financially vulnerable than those without, especially among younger survivors 
[12].
The high costs of treatment have implications for out-of-pocket costs incurred by younger 
patients because most of these treatments require copayments [40]. Given the higher cost of 
treatment for younger versus older women, the out-of-pocket costs borne by younger women 
are likely to be higher. The financial implications of breast cancer treatment costs for 
younger women need to be explored in future studies. New research should seek to identify 
the drivers of those costs using detailed treatment data and the impact these costs have on 
quality of life for younger breast cancer survivors. Multifaceted strategies to counter these 
drivers and reduce costs, and primary prevention efforts that address breast cancer risk 
factors and family history, may be helpful in reducing the treatment costs of breast cancer 
among younger women.
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Fig. 1. 
Adjusted average monthly cost per person from month of diagnosis to18 months for women 
younger than age 45 by AJCC stage of diagnosis
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Fig. 2. 
Direct medical costs of breast cancer 12 months from date of diagnosis by AJCC stage, age 
group, and type of service. Younger, age ≤45; older, age 45–64
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Table 1
Characteristics of women diagnosed with breast cancer in North Carolina, 2003–2010, by age group
Variable Women aged 21–44 years at diagnosis Women aged 45–64 
years at diagnosis
Continuously enrolled 6 
months from diagnosis 
(N = 1106)
Continuously enrolled 
12 months from 
diagnosis (N = 955)
Continuously enrolled 
18 months from 
diagnosis (N = 805)
Continuously enrolled 
12 months from 
diagnosis (N = 4082)
Age (years)a 39.15 39.18 39.25 54.8
Birth year
 1955–1959 1% 1% 1%
 1960–1964 31% 33% 36% -
 1965–1969 41% 41% 40% -
 1970–1974 19% 19% 17% -
 1975–1979 6% 5% 4% -
 1980–1984 2% 2% 2% -
 1985–1989 0.3% 0.1% 0.1% -
Charlson Comorbidity Index (CCI)
 CCI score = 0 96% 96% 96% 89%
 CCI score >0 4% 4% 4% 11%
American Joint Committee on Cancer (AJCC) stage at diagnosis
 Stage I 34% 34% 34% 46%
 Stage II 41% 40% 40% 34%
 Stage III/IV 16% 16% 15% 12%
 Unknown 9% 10% 10% 9%
No. of matched 
comparisons
167,681 134,427 109,218 299,663
aWe matched using birth year intervals; however, we present age in this table for further information
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Table 2
Costs for patients with and without breast cancer, younger than age 45, by service type, North Carolina, 2003–
2010
Patients with breast cancer (N = 
1106)
Patients without breast cancer (N = 
167,681) Excess cost
6 months from diagnosis
 All service types $66,797 ($65,214 to $68,381) $1609 ($25 to $3192) $65,189* ($62,950 to $67,428)
 Physician office $33,894 ($32,805 to $34,982) $667 (-$421-$1756) $33,226* ($31,687 to $34,766)
 Inpatient hospital $2928 ($2583 to $3273) $235 (−109 to $580) $2693* ($2205 to $3180)
 Outpatient hospital $27,629 ($26,264 to $28,995) $402 (−964 to $1768) $27,227* ($25,296 to $29,159)
 Prescription drugs $2346 ($2137 to $2556) $304 ($94 to $513) $2043* ($1746 to $2339)
Breast cancer (N = 955) Comparison (N = 134,427) Excess cost
12 months from diagnosis
 All service types $100,705 ($97,980 to $103,430) $3219 ($493 to $5946) $97,486* ($93,631 to $101,341)
 Physician office $48,985 ($47,224 to $50,745) $1340 (-$421 to $3101) $47,644* ($45,154 to $50,134)
 Inpatient hospital $4296 ($3821 to $4771) $452 (-$24 to $927) $3844* ($3172 to $4516)
 Outpatient hospital $44,250 ($41,990 to $46,510) $797 (-$1464 to $3058) $43,453* ($40,256 to $46,650)
 Prescription drugs $3174 ($2886 to $3463) $630 ($341 to $919) $2544* ($2136 to $2953)
Breast cancer (N = 805) Comparison (N = 109,218) Excess cost
18 months from diagnosis
 All service types $113,683 ($110,104 to $117,262) $4826 ($1248 to $8405) $108,857* ($103,796 to $113,918)
 Physician office $55,315 ($53,012 to $57,618) $2001 (-$302 to $4304) $53,313* ($50,056 to $56,570)
 Inpatient hospital $5410 ($4720 to $6101) $681 (-$10 to $1371) $4729* ($3753 to $5706)
 Outpatient hospital $49,035 ($46,287 to $51,784) $1175 (-$1573 to $3924) $47,860* ($43,973 to $51,747)
 Prescription drugs $3923 ($3543 to $4303) $969 ($589 to $1349) $2954* ($2416 to $3492)
*
Excess cost is significantly different among breast cancer and comparison samples at the 1% level
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Table 3
Treatment costs for breast cancer in women aged 45–64 years and comparison patients, by service type, North 
Carolina, 2003–2010
Breast cancer (N = 4082) Comparison (N = 299,663) Excess cost
12 months from diagnosis
 All service types $80,578 ($79,322 to $81,833) $4841 ($3586 to $6095) $75,737a, b ($73,962 to $77,512)
 Physician office $37,580 ($36,817 to $38,344) $1836 ($1073 to $2599) $35,744a, b ($34,665 to $36,824)
 Inpatient hospital $3480 ($3163 to $3798) $750 ($433 to $1068) $2730a, b ($2281 to $3179)
 Outpatient hospital $36,631 ($35,706 to $37,556) $1140 ($215 to $2064) $35,492a, b ($34,184 to $36,799)
 Prescription drugs $2886 ($2771 to $3001) $1115 ($1000 to $1230) $1771a, b ($1609 to $1934)
a
Excess cost is significantly different among breast cancer and comparison samples at the 1% level
bSignificantly different from women aged 18–44 years at the 1% level
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